.jpeg)
2026-07-14 05:31:14
Idelalisib is an oral PI3Kδ inhibitor indicated for relapsed/refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and small lymphocytic lymphoma (SLL). The recommended dose is 150 mg twice daily. Close monitoring for severe hepatic, pulmonary, and intestinal toxicities, as well as life-threatening diarrhea, is required. This article covers indications, dosing, warnings, and adverse reactions.
2026-07-14 05:26:41
Lorlatinib is an oral tyrosine kinase inhibitor indicated for ALK-positive advanced non-small cell lung cancer (NSCLC). The recommended dose is 100 mg once daily. Treatment must be initiated by a physician experienced in anticancer therapy and preceded by ALK genetic testing. This article covers dosing, mechanism of action, common side effects, and key contraindications.
2026-07-14 05:23:09
Elafibranor is approved for adult patients with primary biliary cholangitis (PBC), used either in combination with ursodeoxycholic acid (UDCA) for those with inadequate response, or as monotherapy for those intolerant to UDCA. The recommended dose is 80 mg once daily orally. No dose adjustment is needed for elderly or renally impaired patients, but use is not recommended in severe hepatic impairment. This summary covers dosing, special population considerations, warnings, and adverse reactions.
2026-07-14 05:19:34
On July 6, 2026, AbbVie announced that the European Commission has granted marketing authorization for TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab (R² regimen) for adult patients with relapsed or refractory follicular lymphoma (R/R FL). The approval is based on the pivotal Phase III EPCORE FL-1 trial, which demonstrated a significant reduction in the risk of disease progression or death compared to R² alone, offering a chemotherapy-free, fixed-duration option for patients in Europe.
2026-07-13 07:43:38
On June 24, 2026, the FDA approved Pfizer’s Ibrance (palbociclib) in combination with anti-HER2 therapy and endocrine therapy for maintenance treatment of HR+/HER2+ advanced breast cancer, based on Phase III PATINA trial results.
2026-07-13 07:34:24
The U.S. FDA approved Gilead’s Trodelvy (sacituzumab govitecan) on June 24, 2026, for first-line treatment of advanced triple-negative breast cancer (TNBC), based on Phase III ASCENT-03 and ASCENT-04 data.
2026-07-10 06:43:53
An in-depth analysis of Cabozantinib's multi-kinase inhibition mechanism and its established role in treating renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer globally.
2026-07-10 06:37:28
This article provides a comprehensive overview of infusion-related reactions (IRRs) associated with Amivantamab. It covers preventive premedication, step-up dosing strategies, and protocols for managing adverse events in clinical settings.
2026-06-30 03:12:23
A roundup of recent cancer case studies and pharmaceutical innovations, highlighting long-term survivors of advanced malignancies and the debut of China's first global-first bispecific ADC drug.
2026-06-30 03:05:30
Lusutrombopag is a small molecule oral thrombopoietin receptor agonist (TPO-RA) indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a planned invasive procedure.
2026-06-29 06:44:46
Pretomanid is a novel nitroimidazole anti-tuberculosis agent and a core component of the BPaL regimen for extensively drug-resistant (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB). This article covers its mechanism of action, efficacy profile, indications and safe use guidelines.
2026-06-26 04:06:33
Fezolinetant is an NK3 receptor antagonist primarily used to treat menopausal hot flashes. This article provides an in-depth analysis of its relationship with depression, including current research evidence, indirect mood benefits from hot flash improvement, and clinical prescribing recommendations to help patients correctly understand the drug's scope of use.
